Straits Times Index
3,302.86 -11.19 (-0.34%) Nikkei
39,175.07 +105.39 (+0.27%) Hang Seng
19,245.92 -390.30 (-1.99%) FTSE 100
8,424.20 +3.94 (+0.05%) Bitcoin USD
71,292.27 +4,620.07 (+6.93%) CMC Crypto 200
1,530.53 +176.11 (+13.00%)
Exicure, Inc. (XCUR)
After hours:
- Business Wire
Exicure, Inc. Reports Third Quarter 2023 Financial Results
CHICAGO, May 16, 2024--Exicure, Inc. (Nasdaq: XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring strategic alternatives to maximize stockholder value.
- Business Wire
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K
CHICAGO, April 22, 2024--Exicure, Inc. ("Exicure" or the "Company") (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC ("Nasdaq") on April 17, 2024 notifying the Company that, as a result of the Company’s failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2023 (the "Form 10-K"), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires listed companies to timely file all pe
- Business Wire
Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis
CHICAGO, February 05, 2024--Exicure, Inc., (NASDAQ:XCUR) a company that historically developed nucleic acid therapies, and Bluejay Therapeutics, Inc., a private clinical stage biopharmaceutical company focused on viral and liver diseases, announced today that Bluejay Therapeutics, Inc. ("Bluejay") and Exicure, Inc. ("Exicure") entered into a patent license agreement to develop cavrotolimod for potential treatment for hepatitis.
